Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility Study - Whether the Administration of the Dronabinol and PEA May Act as a Therapy for Obstructive Sleep Apnea

Trial Profile

Feasibility Study - Whether the Administration of the Dronabinol and PEA May Act as a Therapy for Obstructive Sleep Apnea

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OSA Trial
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 05 Jun 2018 According to a Therapix Biosciences media release, first subject was enrolled on June 05, 2018.
    • 31 May 2018 According to a Therapix Biosciences media release, this study has been started at the Assuta Medical Center in Israel. Top line results are expected in the first half of 2019.
    • 09 Nov 2017 Status changed from planning to recruiting, according to a Therapix Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top